Theranostics Using MCM-41-Based Mesoporous Silica Nanoparticles: Integrating Magnetic Resonance Imaging and Novel Chemotherapy for Breast Cancer Treatment

Keyphrases

• Theranostics 100%
• Magnetic Resonance Imaging 100%
• Breast Cancer Treatment 100%
• Nanomaterials 100%
• Mesoporous Silica Nanoparticles 100%
• Novel Chemotherapy 100%
• MCM-41 100%
• EC50 50%
• MCM-41-NH2 50%
• Breast Cancer Cells 25%
• Normal Human 25%
• Clinical Outcomes 25%
• Drug Delivery 25%
• Cell Toxicity 25%
• MDA-MB-231 25%
• Contrast Agent 25%
• Effective Compounds 25%
• Advanced Breast Cancer 25%
• Cytotoxicity Assay 25%
• Oncologic 25%
• Syngeneic Mouse Model 25%
• Conjugation 25%
• Gd3+ 25%
• Amine Group 25%
• Gadolinium-based Contrast Agents 25%
• Theranostic Agent 25%
• Human Mammary Epithelial Cells 25%
• Physicochemical Characterization 25%
• Chemotherapy Agents 25%
• Commercial Agents 25%
• Effective Interaction 25%
• Mesoionic 25%
• Nanomaterial Synthesis 25%
• MRI Phantom 25%
• Ex Vivo MRI 25%
• Neoplastic Lesions 25%
• Drug Release Assay 25%
• Phantom Study 25%
• Breast Cancer Management 25%
• Interaction with Biomolecules 25%
• Antitumoral Activity 25%
• MRI Imaging 25%
• Mesoporous Silica 25%
• Imaging Capability 25%
• MRI Evaluation 25%
• Drug Incorporation 25%
• Relaxivity 25%
• Magnevist 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Breast Cancer 100%
• Mesoporous Silica Nanoparticle 100%
• Nanomaterial 100%
• Pentetic Acid 60%
• Contrast Medium 40%
• EC50 40%
• Mouse Model 20%
• Normal Human 20%
• Cytotoxicity Assay 20%
• Drug Release 20%
• Mesoporous Silica 20%
• Complexation 20%
• Gadolinium 20%
• Chemotherapy Agent 20%
• Gadolinium Pentetate Meglumine 20%

Material Science

• Magnetic Resonance Imaging 100%
• Mesoporous Silica 100%
• Nanostructured Material 100%
• Silica Nanoparticle 100%
• Contrast Medium 40%
• Complexation 20%
• Gadolinium 20%